GSK spin­out NeRRe splits the pipeline, cre­ates its own spin­out

Five years af­ter NeRRe Ther­a­peu­tics spun out of GSK with some of its un­want­ed work in neu­ro­sciences, the UK biotech is ex­e­cut­ing a spin­out of its own.

NeRRe has tak­en a neu­rokinin-1,3 re­cep­tor an­tag­o­nist — with po­ten­tial as a hor­mone re­place­ment ther­a­py — and hived it off in­to a new biotech called KaNDy Ther­a­peu­tics. Now KaNDy will take it in­to a Phase IIb study for post­menopausal va­so­mo­tor symp­toms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA